

iCare ILLUME



**Revolutionize diabetic eye care
with AI-assisted screening**

For better perception **icare**

iCare ILLUME


Early detection is key to preventing vision loss

Population aging and a declining ophthalmologist-to-patient ratio are straining global eye care systems. Longer waiting times and delays in treatment increase the risk of vision loss for millions. Early detection and diagnosis, particularly for conditions like diabetic retinopathy, is essential to preserve sights and enhance patient outcomes.

Fast and effortless screening for diabetic retinopathy in all care settings

The iCare Screening Solution integrates detail-rich confocal fundus imaging (iCare DRSpplus), cutting-edge AI-powered retinal image analysis (iCare RETCAD), and specialized software used in the screening workflow (iCare ILLUME) to transform early detection, streamline clinical workflows, and enhance the patient care journey.

iCare Screening Solution - swift, fully automated operation




Effortless screening with reduced resource demands

- No dilation required.
- Confocal technology allows scanning through media opacities.
- Designed for automated image acquisition to report generation for all users with one press of a button.
- Seamless digital referral creation.
- Automated imaging process requires minimal staff training.



Why use artificial intelligence in retinal screening?

- **Optimized workflows**
Reduce clinician workload and increase throughput with automated processes.
- **Early detection**
Instantly identify and classify retinal pathologies by severity.
- **Continuity of care**
Monitor changes in patients' retinas during routine visits.
- **Human-comparable accuracy**
Achieve results on par with professional graders.
- **Actionable insights**
Clear visualizations and recommendations in every report.
- **Ensure patient privacy**
Data security and privacy meet the highest standards.



The images provided are for illustrative purposes only. Actual results and appearances may vary.

Take the next step in eye care innovation! With iCare's AI-assisted Screening Solution, you can:

- Detect diabetic retinopathy early and prevent vision loss.
- Save time and resources with automated workflows.
- Enhance the patient experience with faster, more comfortable screenings.

iCare. For better perception.

iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). Our devices cover automated fundus imaging systems, perimeters, and rebound tonometers. iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.

We believe that ophthalmic care must be accessible, effortless, and reliable, and our aim is to establish the next level of eye care.

iCare World Australia

Level 9, 276 Flinders Street
Melbourne Victoria 3000,
Australia
Ph. +61 3 85927079
infoAU@icare-world.com

Centervue S.p.A.

Via San Marco 9H
35129 Padova, Italy
Ph. +39 049 501 8399
info@icare-world.com

Icare Finland Oy

Äyritie 22
01510 Vantaa, Finland
Ph. +358 9 8775 1150
info@icare-world.com

Icare USA, Inc.

8601 Six Forks Rd., Suite 310
Raleigh, NC 27615
Ph. +1 888.422.7313
infoUSA@icare-world.com

www.icare-world.com

icare

For better perception

iCare is a trademark of Icare Finland Oy. Icare Finland Oy, Icare USA, Inc., iCare World Australia Pty Ltd, Thirona Retina B.V. and Centervue S.p.A., are parts of Revenio Group and represent the brand iCare. iCare ILLUME, iCare DRSplus and iCare RETCAD are trademarks or a registered trademarks of Icare Finland Oy in the EU and the USA and/or other countries. Centervue S.P.A. is the legal manufacturer of DRSplus and iCare RETCAD. Not all products, accessories, services or offers are approved in every market. Approved labeling and instructions may vary from one country to another. This material is intended for healthcare professionals only. ©2025 Icare Finland Oy. All rights reserved.